|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
CA1340032C
(en)
|
1987-06-24 |
1998-09-08 |
Jim Haralambidis |
Lucleoside derivatives
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5216141A
(en)
|
1988-06-06 |
1993-06-01 |
Benner Steven A |
Oligonucleotide analogs containing sulfur linkages
|
|
US5328470A
(en)
*
|
1989-03-31 |
1994-07-12 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5591722A
(en)
|
1989-09-15 |
1997-01-07 |
Southern Research Institute |
2'-deoxy-4'-thioribonucleosides and their antiviral activity
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
JPH05504552A
(ja)
|
1989-10-24 |
1993-07-15 |
ギリアド サイエンシズ，インコーポレイテッド |
２’位が改変されたオリゴヌクレオチド
|
|
EP0800830A3
(en)
|
1989-11-03 |
1999-03-17 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5506351A
(en)
|
1992-07-23 |
1996-04-09 |
Isis Pharmaceuticals |
Process for the preparation of 2'-O-alkyl guanosine and related compounds
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
US5212295A
(en)
|
1990-01-11 |
1993-05-18 |
Isis Pharmaceuticals |
Monomers for preparation of oligonucleotides having chiral phosphorus linkages
|
|
US5670633A
(en)
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
WO1993007883A1
(en)
|
1991-10-24 |
1993-04-29 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5321131A
(en)
*
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US6262241B1
(en)
|
1990-08-13 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Compound for detecting and modulating RNA activity and gene expression
|
|
US5214134A
(en)
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
US5359044A
(en)
*
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
US20030206887A1
(en)
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
|
EP0577558A2
(de)
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
|
NL9201440A
(nl)
|
1992-08-11 |
1994-03-01 |
Univ Leiden |
Triantennaire clusterglycosiden, hun bereiding en toepassing.
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
EP0691977B1
(en)
|
1993-03-31 |
1997-11-26 |
Sanofi |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
US5571902A
(en)
|
1993-07-29 |
1996-11-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
|
US5519134A
(en)
|
1994-01-11 |
1996-05-21 |
Isis Pharmaceuticals, Inc. |
Pyrrolidine-containing monomers and oligomers
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5554746A
(en)
|
1994-05-16 |
1996-09-10 |
Isis Pharmaceuticals, Inc. |
Lactam nucleic acids
|
|
US5597909A
(en)
|
1994-08-25 |
1997-01-28 |
Chiron Corporation |
Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
|
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
|
US5856459A
(en)
|
1995-06-06 |
1999-01-05 |
Hybridon, Inc. |
Oligonucleotides specific for hepatitis B virus
|
|
US5985662A
(en)
|
1995-07-13 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of hepatitis B virus replication
|
|
US6127533A
(en)
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
|
US6271358B1
(en)
|
1998-07-27 |
2001-08-07 |
Isis Pharmaceuticals, Inc. |
RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
|
|
AU6430599A
(en)
|
1998-10-09 |
2000-05-01 |
Cytogenix, Inc. |
Enzymatic synthesis of ssdna
|
|
US5977341A
(en)
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
|
CA2365625A1
(en)
|
1999-03-10 |
2000-09-14 |
Phogen Limited |
Delivery of substances to cells
|
|
DK1102785T3
(da)
|
1999-06-07 |
2013-05-13 |
Arrowhead Res Corp |
Sammensætninger til lægemiddeltilførsel ved anvendelse af pH-følsomme molekyler
|
|
US7019113B2
(en)
|
1999-06-07 |
2006-03-28 |
Mirus Bio Corporation |
Reversible modification of membrane interaction
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
JP2004532022A
(ja)
|
2001-03-26 |
2004-10-21 |
サーナ・セラピューティクス・インコーポレイテッド |
Ｂ型肝炎ウイルスおよびｃ型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
|
|
US20060217331A1
(en)
*
|
2001-05-18 |
2006-09-28 |
Sirna Therapeutics, Inc. |
Chemically modified double stranded nucleic acid molecules that mediate RNA interference
|
|
AU2004266311B2
(en)
|
2001-05-18 |
2009-07-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9994853B2
(en)
*
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
|
US20030198627A1
(en)
|
2001-09-01 |
2003-10-23 |
Gert-Jan Arts |
siRNA knockout assay method and constructs
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
US6635428B2
(en)
|
2001-12-04 |
2003-10-21 |
Quest Diagnostics Investments Incorporated |
Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
|
|
ATE529512T1
(de)
|
2002-02-01 |
2011-11-15 |
Life Technologies Corp |
Doppelsträngige oligonukleotide
|
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
EP1857547B2
(en)
|
2002-08-05 |
2020-12-02 |
Silence Therapeutics GmbH |
Further novel forms of interfering RNA molecules
|
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
WO2004044139A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
|
US7816337B2
(en)
|
2003-02-18 |
2010-10-19 |
Roche Madison Inc. |
Reversible attachment of a membrane active polymer to a polynucleotide
|
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
|
CN1257284C
(zh)
|
2003-03-05 |
2006-05-24 |
北京博奥生物芯片有限责任公司 |
一种体外阻断乙肝病毒表达的方法
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
WO2005009346A2
(en)
|
2003-06-24 |
2005-02-03 |
Mirus Corporation |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
|
WO2005021751A1
(en)
|
2003-09-01 |
2005-03-10 |
Patrick Arbuthnot |
A self-processing rna expression cassette
|
|
US20080145346A1
(en)
|
2003-12-16 |
2008-06-19 |
Agency For Science, Technology And Research |
Methods And Compounds For Altering The Load Of Hepatitis Virus
|
|
CA2553211A1
(en)
|
2004-01-12 |
2005-07-21 |
Genesense Technologies Inc. |
Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
|
|
US20050277610A1
(en)
|
2004-03-15 |
2005-12-15 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
|
|
CN101052717A
(zh)
|
2004-05-11 |
2007-10-10 |
α基因株式会社 |
诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
|
|
EP1786905B1
(en)
|
2004-08-18 |
2011-08-03 |
Lorus Therapeutics Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
KR20100060018A
(ko)
|
2005-03-09 |
2010-06-04 |
재단법인 목암생명공학연구소 |
작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
|
|
JP2008537551A
(ja)
|
2005-03-31 |
2008-09-18 |
カランド ファーマシューティカルズ， インコーポレイテッド |
リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
|
|
CN101426912A
(zh)
|
2005-08-17 |
2009-05-06 |
瑟纳治疗公司 |
介导rna干扰的化学修饰短干扰核酸分子
|
|
KR20080036650A
(ko)
|
2005-08-17 |
2008-04-28 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
Ｒｎａ 간섭을 매개하는 화학적으로 변형된 짧은 간섭 핵산분자
|
|
RU2418068C2
(ru)
|
2005-08-17 |
2011-05-10 |
Сирна Терапьютикс, Инк. |
Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
|
|
EP2202239A1
(en)
|
2005-11-01 |
2010-06-30 |
Alnylam Pharmaceuticals Inc. |
RNAI inhibition of influenza virus replication
|
|
CN100447243C
(zh)
|
2005-11-15 |
2008-12-31 |
中国人民解放军第四军医大学 |
HBV特异性干涉靶位点基因及其siRNA和其在抗HBV感染中的应用
|
|
CN101024088A
(zh)
|
2006-02-20 |
2007-08-29 |
桂林医学院 |
抗乙型肝炎病毒微小核糖核酸干扰分子及其设计方法
|
|
KR101133799B1
(ko)
|
2006-08-18 |
2012-04-24 |
에프. 호프만-라 로슈 아게 |
폴리뉴클레오타이드의 생체내 전달을 위한 다가접합체
|
|
WO2008119000A1
(en)
|
2007-03-27 |
2008-10-02 |
University Of Iowa Research Foundation |
Zinc-finger nuclease and rna interference mediated inactivation of viral genomes
|
|
WO2008131419A2
(en)
|
2007-04-23 |
2008-10-30 |
Alnylam Pharmaceuticals, Inc. |
Glycoconjugates of rna interference agents
|
|
EP2164965B1
(en)
|
2007-05-29 |
2013-09-11 |
University Of The Witwatersrand, Johannesburg |
A primary micro rna expression cassette
|
|
KR20100069679A
(ko)
|
2007-09-17 |
2010-06-24 |
재단법인 목암생명공학연구소 |
ＨＢＶ 또는 ＨＣＶ의 유전자 발현을 하향 조절하는 ｓｉＲＮＡ의 혈청 안정성 향상 및 면역 반응 저감 방법
|
|
EP2205740A2
(en)
|
2007-10-02 |
2010-07-14 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
|
WO2009073809A2
(en)
|
2007-12-04 |
2009-06-11 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
CA3044980A1
(en)
|
2008-04-11 |
2009-10-15 |
Alnylam Pharmaceuticals, Inc. |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
CN101603042B
(zh)
|
2008-06-13 |
2013-05-01 |
厦门大学 |
可用于乙型肝炎病毒感染治疗的rna干扰靶点
|
|
CN103275971A
(zh)
*
|
2008-06-13 |
2013-09-04 |
厦门大学 |
可用于乙型肝炎病毒感染治疗的rna干扰靶点
|
|
CN101322847A
(zh)
|
2008-06-23 |
2008-12-17 |
淮安市第四人民医院 |
基于siRNA池干扰的复合载体介导的抗乙肝病毒基因药物
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
KR20110110776A
(ko)
|
2008-12-18 |
2011-10-07 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
WO2010129023A2
(en)
|
2009-04-28 |
2010-11-11 |
President And Fellows Of Harvard College |
Supercharged proteins for cell penetration
|
|
CA2761106C
(en)
|
2009-05-05 |
2019-01-15 |
Miragen Therapeutics |
Lipophilic polynucleotide conjugates
|
|
US8207138B2
(en)
|
2009-05-19 |
2012-06-26 |
Medtronic, Inc. |
Methods and devices for improved efficiency of RNA delivery to cells
|
|
SG177560A1
(en)
|
2009-07-06 |
2012-03-29 |
Hoffmann La Roche |
Bi-specific digoxigenin binding antibodies
|
|
US20110152349A1
(en)
|
2009-12-18 |
2011-06-23 |
Anke Geick |
Compositions and methods for inhibiting expression of il-18 genes
|
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
|
WO2011104169A1
(en)
|
2010-02-24 |
2011-09-01 |
F. Hoffmann-La Roche Ag |
Compositions for targeted delivery of sirna
|
|
EP2390327A1
(en)
|
2010-05-27 |
2011-11-30 |
Sylentis S.A. |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
SI2606134T1
(sl)
|
2010-08-17 |
2019-08-30 |
Sirna Therapeutics, Inc. |
RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
|
|
WO2012037254A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
MODIFIED iRNA AGENTS
|
|
CN101948834B
(zh)
|
2010-09-16 |
2012-07-04 |
山东大学 |
用于治疗HBV的siRNA
|
|
BR112013010525A2
(pt)
|
2010-10-28 |
2016-08-02 |
Benitec Biopharma Ltd |
tratamento de hbv
|
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
KR20130108655A
(ko)
|
2010-12-29 |
2013-10-04 |
에프. 호프만-라 로슈 아게 |
핵산의 세포내 전달을 위한 소분자 접합체
|
|
KR102055331B1
(ko)
*
|
2011-04-21 |
2019-12-12 |
아이오니스 파마수티컬즈, 인코포레이티드 |
B형 간염 바이러스(hbv) 발현 조절
|
|
AU2012258220B2
(en)
|
2011-05-18 |
2017-01-19 |
Janssen Sciences Ireland Uc |
Quinazoline derivatives for the treatment of viral infections and further diseases
|
|
EA202191537A1
(ru)
*
|
2011-06-30 |
2022-01-31 |
Эрроухэд Фармасьютикалс, Инк. |
Композиции и способы ингибирования экспрессии генов вируса гепатита в
|
|
TWI623618B
(zh)
|
2011-07-12 |
2018-05-11 |
傳斯堅公司 |
Ｈｂｖ聚合酶突變體
|
|
HK1199736A1
(en)
|
2011-08-26 |
2015-07-17 |
箭头研究公司 |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
AU2012340159B2
(en)
|
2011-11-18 |
2017-09-07 |
Alnylam Pharmaceuticals, Inc. |
RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
|
|
US8933047B2
(en)
|
2012-04-18 |
2015-01-13 |
Arrowhead Madison Inc. |
Poly(acrylate) polymers for in vivo nucleic acid delivery
|
|
WO2013159109A1
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Modulation of hepatitis b virus (hbv) expression
|
|
US9212363B2
(en)
|
2012-05-11 |
2015-12-15 |
City Of Hope |
RNAI molecules with non-watson crick pairing based on artificial mutation consensus sequences to counter escape mutations
|
|
WO2013176772A1
(en)
|
2012-05-25 |
2013-11-28 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
CN103333890B
(zh)
*
|
2012-12-21 |
2015-04-15 |
厦门成坤生物技术有限公司 |
治疗乙型病毒性肝炎的rna干扰制剂
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
EP3052107B1
(en)
|
2013-10-04 |
2018-05-02 |
Novartis AG |
Organic compounds to treat hepatitis b virus
|
|
EP3137115B1
(en)
|
2014-05-01 |
2020-10-14 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
|
CN104059916A
(zh)
|
2014-06-17 |
2014-09-24 |
湖北医药学院附属太和医院 |
乙肝病毒特异性的microRNA样siRNA序列及其用途
|
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
|
JOP20200092A1
(ar)
*
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
US20170137821A1
(en)
|
2015-07-17 |
2017-05-18 |
Arcturus Therapeutics, Inc. |
Molecules and agents for treating hepatitis b virus
|
|
CN108136206B
(zh)
|
2015-07-17 |
2021-10-15 |
阿克丘勒斯治疗公司 |
抗乙型肝炎病毒的组合物和药剂及其用途
|
|
WO2017019891A2
(en)
|
2015-07-29 |
2017-02-02 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing hepatitis b virus gene expression
|
|
JP7336191B2
(ja)
|
2015-08-07 |
2023-08-31 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
Ｂ型肝炎ウイルス感染に対するＲＮＡｉ療法
|
|
US10246709B2
(en)
|
2016-03-07 |
2019-04-02 |
Arrowhead Pharmaceuticals, Inc. |
Targeting ligands for therapeutic compounds
|
|
MA45478A
(fr)
|
2016-04-11 |
2019-02-20 |
Arbutus Biopharma Corp |
Compositions de conjugués d'acides nucléiques ciblés
|
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
|
CN116942841A
(zh)
|
2016-09-02 |
2023-10-27 |
箭头药业股份有限公司 |
靶向配体
|
|
EA202091517A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
|
|
US11021692B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis B virus (HBV) vaccines and uses thereof
|
|
US11020476B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
|
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
AU2020219355A1
(en)
|
2019-02-07 |
2021-09-30 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for Hepatitis B virus infection
|
|
WO2020214974A1
(en)
|
2019-04-18 |
2020-10-22 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
SG11202112240VA
(en)
|
2019-05-13 |
2021-12-30 |
Vir Biotechnology Inc |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
|
KR20220042116A
(ko)
|
2019-06-18 |
2022-04-04 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
|
|
CA3188801A1
(en)
|
2020-07-08 |
2022-01-13 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
WO2022133230A1
(en)
|
2020-12-18 |
2022-06-23 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|